XOMA Royalty (NASDAQ:XOMA) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

XOMA Royalty (NASDAQ:XOMA) announced its quarterly earnings results on Tuesday. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.02), FiscalAI reports. The firm had revenue of $12.32 million for the quarter, compared to analyst estimates of $13.91 million. XOMA Royalty had a net margin of 45.75% and a return on equity of 10.32%.

XOMA Royalty Trading Up 0.6%

XOMA stock traded up $0.25 during mid-day trading on Tuesday, reaching $41.75. 83,680 shares of the stock traded hands, compared to its average volume of 362,370. The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 1.15. XOMA Royalty has a 52-week low of $22.29 and a 52-week high of $42.81. The company has a market cap of $497.66 million, a P/E ratio of 28.60 and a beta of 0.90. The stock’s fifty day moving average is $33.63 and its 200-day moving average is $30.37.

Institutional Trading of XOMA Royalty

Hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. lifted its stake in XOMA Royalty by 3,436.4% during the third quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 756 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of XOMA Royalty by 203.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,523 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of XOMA Royalty by 13.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 543 shares during the period. Raymond James Financial Inc. acquired a new position in shares of XOMA Royalty in the 2nd quarter valued at about $116,000. Finally, BNP Paribas Financial Markets grew its stake in XOMA Royalty by 266.6% in the third quarter. BNP Paribas Financial Markets now owns 3,226 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 2,346 shares in the last quarter. 95.92% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. TD Cowen raised shares of XOMA Royalty to a “hold” rating in a report on Friday, February 13th. Zacks Research upgraded shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. HC Wainwright cut shares of XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price target on the stock. in a research report on Thursday, April 30th. Leerink Partners reiterated an “outperform” rating on shares of XOMA Royalty in a research report on Tuesday, February 24th. Finally, Lucid Cap Mkts downgraded XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 27th. Two analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $53.75.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.